Motse Kagiso G, Mashabane Mduduzi J
School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, South Africa; Division of Nephrology, Chris Hani Baragwanath Academic Hospital, South Africa.
S Afr Med J. 2016 Aug 2;106(9):886-7. doi: 10.7196/SAMJ.2016.v106i9.10636.
Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR), used as an immunosuppressant for solid-organ transplant recipients and patients with autoimmune disorders. We report a case of lymphoedema, a rare complication of sirolimus, and discuss the mechanism of drug action, the adverse effects and the challenges of treating a kidney transplant recipient with this complication in a resource-limited environment. Lymphoedema is a rare complication of sirolimus, and the mechanisms are not completely understood; however, early recognition can prevent permanent disfiguration. This case highlights the need for early recognition of adverse drug effects and further research into their pathophysiology and management.
西罗莫司是一种哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂，用作实体器官移植受者和自身免疫性疾病患者的免疫抑制剂。我们报告了一例淋巴水肿病例，这是西罗莫司一种罕见的并发症，并讨论了药物作用机制、不良反应以及在资源有限的环境中治疗患有这种并发症的肾移植受者所面临的挑战。淋巴水肿是西罗莫司罕见的并发症，其机制尚未完全明确；然而，早期识别可预防永久性毁容。该病例凸显了早期识别药物不良反应以及对其病理生理学和管理进行进一步研究的必要性。
